Miami, FL / Global — February 12, 2026
Global Stem Cells Group, a publicly traded leader in regenerative medicine and advanced cellular therapies, today announced the official launch of ISSCA AI™ Clinical Intelligence Platform, a next-generation artificial intelligence system developed by its education and innovation division, ISSCA (International Society for Stem Cell Application).
This milestone marks a transformative step in the convergence of artificial intelligence, regenerative medicine, and clinical operations, positioning the company at the forefront of the next evolution in healthcare delivery.
A New Category: Clinical Intelligence for Regenerative Medicine
The ISSCA AI™ platform is designed to transform complex clinical data into actionable medical insights, enabling physicians to enhance diagnostic precision, optimize treatment protocols, and streamline practice operations.
Unlike traditional healthcare software, ISSCA AI™ represents a comprehensive clinical intelligence ecosystem, integrating:
- AI-assisted diagnostics and patient intake
- Intelligent regenerative protocol design
- Predictive analytics and biological age modeling
- Patient follow-up automation and engagement systems
- Full clinical workflow and practice optimization
This approach aligns with the global shift toward AI-powered healthcare systems that augment physician decision-making while reducing administrative burden and improving patient outcomes.
Strategic Positioning: From Education to Infrastructure
With over 15 years of global leadership in physician training across more than 30 countries, ISSCA now evolves from an education-driven organization into a technology-enabled clinical infrastructure provider.
The ISSCA AI™ platform is purpose-built for:
- Regenerative medicine clinics
- Longevity and anti-aging centers
- Integrative and functional medicine practices
- Advanced biologics and cellular therapy providers
By embedding AI into clinical workflows, the platform enables practitioners to scale personalized medicine while maintaining clinical control and scientific rigor.
Industry Context: AI as the Next Operating System of Medicine
The launch comes at a pivotal moment in healthcare, where artificial intelligence is rapidly becoming foundational infrastructure:
- Over two-thirds of physicians already use some form of AI in clinical practice
- AI-driven tools are demonstrating measurable improvements in efficiency, accuracy, and patient throughput
- Clinical AI systems are increasingly capable of real-time decision support, predictive modeling, and workflow automation
Industry experts project that AI will become the operating system of modern medical practices, particularly in data-intensive fields such as regenerative and longevity medicine.
ISSCA AI™ directly addresses this shift by providing a unified platform that bridges clinical insight, operational efficiency, and patient experience.
Executive Commentary
Benito Novas, CEO of Global Stem Cells Group, commented:
“The future of medicine is not just biological—it is computational. With ISSCA AI™, we are empowering physicians with a system that enhances their intelligence, not replaces it. This is about enabling better decisions, better outcomes, and ultimately, better medicine at scale.”
Competitive Differentiation
ISSCA AI™ distinguishes itself from existing healthcare AI tools through:
- Domain specialization in regenerative and longevity medicine
- Integration of clinical, operational, and patient engagement layers
- Alignment with real-world physician workflows, not just academic models
- A global distribution network through ISSCA’s physician ecosystem
This positions Global Stem Cells Group to capture value not only as a clinical and educational leader, but as a technology innovator in precision medicine infrastructure.
Market Opportunity
The global AI in healthcare market is experiencing rapid expansion, driven by:
- Rising demand for personalized medicine
- Increasing clinical data complexity
- Physician burnout linked to administrative overload
- The need for scalable, technology-enabled care models
ISSCA AI™ addresses these challenges directly, offering a platform capable of increasing efficiency, reducing cognitive load, and enhancing clinical outcomes simultaneously.
Forward-Looking Vision
The launch of ISSCA AI™ represents the first phase of a broader strategic roadmap, including:
- Expansion into digital twins and predictive longevity modeling
- Integration with cellular therapy and biologics platforms (Cellgenic)
- Development of AI-driven clinical networks across global markets
- Continuous learning systems powered by real-world clinical data
About Global Stem Cells Group
Global Stem Cells Group is a global leader in regenerative medicine, combining clinical services, physician training, and biotechnology commercialization. Through its divisions—including ISSCA (International Society for Stem Cell Application) and Cellgenic—the company operates at the intersection of science, education, and innovation.
Media & Investor Contact
Sarah Barroso
Info@stemcellsgroup.com
[Website: www.stemcellsgroup.com]
Forward-Looking Statements
This press release contains forward-looking statements regarding future developments, performance, and market opportunities. Actual results may differ materially based on regulatory, technological, and market conditions.
